536 J ournal of Medicinal Chemistry, 2002, Vol. 45, No. 2
Brief Articles
(7) Kato, K. Isoprenoid addition to ras protein is the critical
modification for its membrane association and transforming
activity. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 6403-6407.
(8) Hancock, J . F.; Magee, J . E.; Marshall, C. J . All ras proteins
are poly isoprenylated but only some are palmitoylated. Cell
1989, 57, 1167-1177.
Liu, M. Identification of pharmacokinetically stable 3,10-di-
bromo-8-chlorobenzocycloheptapyridine farnesyl protein trans-
ferase inhibitors with potent enzyme and cellular activities. J .
Med. Chem. 1999, 42, 2651-2661.
(26) Eskens, F. A. L. M.; Stoter, G.; Verweij, J . Farnesyl transferase
inhibitors: current developments and future perspectives. Can-
cer Treat. Rev. 2000, 26, 319-332.
(9) Gibbs, J . B. Ras C-terminal processing enzymes. New drug
targets. Cell 1991, 65, 1-4.
(27) Zujewski, J .; Horak, I. D.; Bol, C. J .; Woestenborghs, R.; Bowden,
C.; End, D. W.; Piotrovsky, V. K.; Chiao, J .; Belly, R. T.; Todd,
A.; Kopp, W. C.; Kohler, D. R.; Chow, C.; Noone, M.; Hakim, F.
T.; Larkin, G.; Gress, R. E.; Nussenblatt, R. B.; Kremer, A. B.;
Cowan, K. H. Phase I and pharmacokinetic study of farnesyl
protein transferase inhibitor R-115777 in advanced cancer. J .
Clin. Oncol. 2000, 18, 927-941.
(10) Leonard, D. M. Ras farnesyltransferase: A new therapeutic
target. J . Med. Chem. 1997, 40, 2971-2990.
(11) Burns, C. J .; Guitton, J . D.; Baudoin, B.; Lelievre, Y.; Duchesne,
M.; Parker, F.; Fromage, N.; Commerc¸on, A. Novel conforma-
tionally extended naphthalene-based inhibitors of farnesyltrans-
ferase. J . Med. Chem. 1997, 40, 1763-1767.
(12) Sebti, S. M.; Hamilton A. D. New approches to anticancer drug
design based on the inhibition of farnesyltransferase. Drug
Discovery Today 1998, 3, 26-33.
(13) Williams, T. M. Inhibitors of protein prenylation 1999. Expert
Opin. Ther. Pat. 1999, 9, 1263-1280.
(28) Eskens, F. A. L. M.; Awada, A.; Cutler, D. L.; de J onge, M. J .;
Luyten, G. P.; Faber, M. N.; Statkevich, P.; Sparreboom, A.;
Verweij, J .; Hanauske, A. R.; Piccart, M. J . Phase
I and
pharmacokinetic studies of the oral farnesyltransferase inhibitor
SCH-66636 given twice daily to patients with advanced solid
tumors. Clin. Oncol. 2001, 19, 1167-1175.
(14) Park, H. W.; Boduluri, S. R.; Moomaw, J . F.; Casey, P. J .; Beese,
L. S. Crystal structure of protein farnesyltransferase at 2.25
angstrom resolution. Science 1997, 275, 1800-1804.
(29) Ashar, H. R.; J ames, L.; Gray, K.; Carr, D.; McGuirk, M.;
Maxwell, E.; Black, S.; Armstrong, L.; Doll, R. J .; Taveras, A.
G.; Bishop, W. R.; Kirschmeier, P. The farnesyl transferase
inhibitor SCH-66336 induces a G2 f M or G1 pause in sensitive
human tumor cell lines. Exp. Cell Res. 2001, 262, 17-27.
(30) Khan, S. G.; Mukthar, H.; Agarwal, R. A rapid and convenient
filter-binding assay for Ras p21 processing enzyme farnesyl
transferase. J . Biochem. Biophys. Methods 1995, 30, 133-144.
(31) J ames, G. L.; Goldstein, J . L.; Brown, M. S.; Rawson, T. E.;
Somers, T. C.; McDowell, R. S.; Crowley, C. W.; Lucas, B. K.;
Levinson, A. D.; Marsters, J . C., J r. Benzodiazepine peptidomi-
metics: potent inhibitors of Ras farnesylation in animal cells.
Science 1993, 260, 1937-1942.
(32) MacTough, S. C.; deSolms, S. J .; Shaw, A. W.; Abrams, M. T.;
Ciccarone, T. M.; Davide, J . P.; Hamilton, K. A.; Hutchinson, J .
H.; Koblan, K. S.; Kohl, N. E.; Lobell, R. B.; Robinson, R. G.;
Graham, S. L. Diaryl ether inhibitors of farnesyl-protein trans-
ferase. Bioorg. Med. Chem. Lett. 2001, 11, 1257-1260.
(33) Bergman, J . M.; Abrams, M. T.; Davide, J . P.; Greenberg, I. B.;
Robinson, R. G.; Buser, C. A.; Huber, H. E.; Koblan, K. S.; Kohl,
N. E.; Lobell, R. B.; Graham, S. L.; Hartman, G. D.; Williams,
T. M.; Dinsmore, C. J . Aryloxy substituted N-arylpiperazinones
as dual inhibitors of farnesyltransferase and geranylgeranyl-
transferase-I. Bioorg. Med. Chem. Lett. 2001, 11, 1411-1415.
(34) Kohl, N. E.; Mosser, S. D.; deSolms, S. J .; Giuliani, E. A.;
Pompliano, D. L.; Graham, S. L.; Smith, R. L.; Scolnick, E. M.;
Oliff, A.; Gibbs, J . B. Selective inhibition of ras-dependent
transformation by a farnesyltransferase inhibitor. Science 1993,
260, 1934-1937.
(35) Campion, C.; Davidson, A. H.; Dickens, J . P.; Grimmin, M. J .
Preparation of N-[4-(N-hydroxyamino)succinyl]amino acid amides
as collagenase inhibitors. PCT Int. Appl. WO 9005719; Chem.
Abstr. 1990, 113, 212677c.
(36) Erlenmeyer, H.; Morel, C. J . Structural and chemical study. VII
About thiazole-4,5-dicarboxylic acid and thiazole-4-carboxylic
acid. Helv. Chim. Acta 1945, 28, 362-364.
(37) Cordi, A. A.; Snyers, M. P.; Giraud-Mangin, D.; Van der Maesen,
C.; Van Hoeck, J . P.; Beuze, S.; Ellens, E.; Napora, F.; Gillet, C.
L.; Gorissen, H.; Calderon, P.; Remacle, M. D.; J anssens de
Varebeke, P.; Van Dorsser, W.; Roba, J. Synthesis and structure-
activity of 4(5)-(2,2-diphenylethyl)imidazoles as new R2-adreno-
ceptor antagonists. Eur. J . Med. Chem. 1990, 25, 557-568.
(38) Martinez, J . Synthesis and biological activities of some pseudo
peptide analogues of tetragastrin: the importance of the peptide
backbone. J . Med. Chem. 1985, 28, 1874-1879.
(15) Breslin, M. J .; J ane deSolms, S.; Giuliani, E. A.; Stokker, G. E.;
Graham, S. L.; Pompliano, D. L.; Mosser, S. D.; Hamilton, K.
A.; Hutchinson, J . H. Potent, non-thiol inhibitors of farnesyl-
transferase. Bioorg. Med. Chem. Lett. 1998, 8, 3311-3316.
(16) Quian, Y.; Marugan, J . J .; Fossum, R. D.; Vogt, A.; Sebti, S. M.;
Hamilton, A. D. Probing the hydrophobic pocket of farnesyl-
transferase: aromatic substitution of CAAX peptidomimetics
leads to highly potent inhibitors. Bioorg. Med. Chem. 1999, 7,
3011-3024.
(17) Augeri, D. J .; O’Connor, S. J .; J anowick, D.; Szczepankiewicz,
B.; Sullivan, G.; Larsen, J .; Kalvin, D.; Cohen, J .; Devine, E.;
Zhang, H.; Cherian, S.; Saeed, B.; Ng, S.-C.; Rosenberg, S. Potent
and selective non-cysteine-containing inhibitors of protein far-
nesyltransferase. J . Med. Chem. 1998, 41, 4288-4300.
(18) O’Connor, S. J .; Barr, K. J .; Wang, L.; Sorensen, B. K.; Tasker,
A. S.; Sham, H.; Ng, S.-C.; Cohen, J .; Devine, E.; Cherian, S.;
Saeed, B.; Zhang, H.; Lee, J . Y.; Warner, R.; Tahir, S.; Kovar,
P.; Ewing, P.; Alder, J .; Mitten, M.; Leal, J .; Marsh, K.; Bauch,
J .; Hoffman, D. J .; Sebti, S. M.; Rosenberg, S. H. Second-
generation peptidomimetic inhibitors of protein farnesyltrans-
ferase demonstrating improved cellular potency and significant
in vivo efficacy. J . Med. Chem. 1999, 42, 3701-3710.
(19) Henry, K. J .; Wasicak, J .; Tasker, A. S.; Cohen, J .; Ewing, P.;
Mitten, M.; Larsen, J . J .; Kalvin, D. M.; Swenson, R.; Ng, S.-C.;
Saeed, B.; Cherian, S.; Sham, H.; Rosenberg, S. H. Discovery of
a series of cyclohexylethylamine-containing protein farnesyl-
transferase inhibitors exhibiting potent cellular activity. J . Med.
Chem. 1999, 42, 4844-4852.
(20) Anthony, N. J .; Gomez, R. P.; Schaber, M. D.; Mosser, S. D.;
Hamilton, K. A.; O’Neil, T. J .; Koblan, K. S.; Graham, S. L.;
Hartman, G. D.; Shah, D.; Rands, E.; Kohl, N. E.; Gibbs, J . B.;
Oliff, A. I. Design and in vivo analysis of potent non-thiol
inhibitors of farnesyl protein transferase. J . Med. Chem. 1999,
42, 3356-3368.
(21) Ding, C. Z.; Batorsky, R.; Bhide, R.; Chao, H. J .; Cho, Y.; Chong,
S.; Gullo-Brown, J .; Guo, P.; Kim, S. H.; Lee, F.; Leftheris, K.;
Miller, A.; Mitt, T.; Patel, M.; Penhallow, B. A.; Ricca, C.; Rose,
W. C.; Schmidt, R.; Slusarchyk, W. A.; Vite, G.; Yan, N.; Manne,
V.; Hunt, J . T. Discovery and structure-activity relationships
of imidazole-containing tetrahydrobenzodiazepine inhibitors of
farnesyltransferase. J . Med. Chem. 1999, 42, 5241-5253.
(22) Dinsmore, C. J .; Williams, T. M.; O’Neill, T. J .; Liu, D.; Rands,
E.; Culberson, J . C.; Lobell, R. B.; Koblan, K. S.; Kohl, N. E.;
Gibbs, J . B.; Oliff, A. I.; Graham, S. L.; Hartman, G. D.
Imidazole-containing diarylether and diarylsulfone inhibitors of
farnesyl-protein transferase. Bioorg. Med. Chem. Lett. 1999, 9,
3301-3306.
(39) Cassidy, P. B.; Dolence, J . M.; Poulter, C. D. Continuous
fluorescence assay for prenyl transferases. Methods Enzymol.
1995, 250, 30-43.
(40) Garcia, A. M.; Rowell, C.; Ackermann, K.; Kowalczyk, J . J .;
Lewis, M. D. Peptidomimetic inhibitors of Ras farnesylation and
function in whole cells. J . Biol. Chem. 1993, 268, 18415-18418.
(41) Hamilton, A. D.; Sebti, S. M. Inhibitors of Ras farnesyltrans-
ferase as novel antitumor agents. Drug News Perspect. 1995, 8,
138-145.
(42) Qian, Y.; Vogt, A.; Sebti, S.; Hamilton, A. Design and synthesis
of non-peptide Ras CAAX mimetics as potent farnesyltransferase
inhibitors. J . Med. Chem. 1996, 39, 217-223.
(43) Christiansen, D. W. Structural Biology of Zinc. In Metallopro-
teins: Structural Aspects; Edsall, J . T., Anfinsen C. B., Richards,
F. M., Eisenberg, D. S., Eds.; Academic Press: San Diego, CA,
1991; Vol. 42, pp 281-355.
(23) Ciccarone, T. M.; MacTough, S. C.; Williams, T. M.; Dinsmore,
C. J .; O’Neill, T. J .; Shah, D.; Culberson, J . C.; Koblan, K. S.;
Kohl, N. E.; Gibbs, J . B.; Oliff, A. I.; Graham, S. L.; Hartman,
G. D. Non-thiol 3-aminomethylbenzamide inhibitors of farnesyl-
protein transferase. Bioorg. Med. Chem. Lett. 1999, 9, 1991-
1996.
(24) Perola, E.; Xu, K.; Kollmeyer, T. M.; Kaufman, S. H.; Prender-
gast, F. G.; Pang, Y. P. Successful virtual screening of a chemical
database for farnesyltransferase inhibitor leads. J . Med. Chem.
2000, 43, 401-408.
(25) Taveras, A. G.; Deskus, J .; Chao, J .; Vaccaro, C. J .; Njoroge, F.
G.; Vibulbhan, B.; Pinto, P.; Remiszewski, S.; del Rosario, J .;
Doll, R. J .; Alvarez, C.; Lalwani, T.; Mallams, A. K.; Rossman,
R. R.; Afonso, A.; Girijavallabhan, V. M.; Ganguly, A. K.;
Pramanik, B.; Heimark, L.; Bishop, W. R.; Wang, L.; Kirshmeier,
P.; J ames, L.; Carr, D.; Patton, R.; Bryant, M. S.; Nomeir, A. A.;
(44) Strickland, C. L.; Windsor, W. T.; Syto, R.; Wang, L.; Bond, R.;
Wu, Z.; Schwartz, J .; Le, H. V.; Beese, L. S.; Weber, P. C. Crystal
structure of farnesyl protein transferase complexed with a CaaX
peptide and farnesyl diphosphate analogue. Biochemistry 1998,
37, 16601-16611.
J M010297R